CryoPort, Inc. CYRX
- Market cap
- $881.3M
- P/E
- 0.0×
Follow CYRX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.03 | 1.96 | 6.66 | 8.28 | 13.01 | 45.95 | 15.63 | 9.00 | 5.32 | 4.58 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 3.49 | 10.40 | 16.88 | 25.02 | 63.36 | 86.30 | 59.71 | 26.01 | 20.11 | 11.44 |
High Price
|
|||
| 37 | 57 | 92 | 125 | 625 | 847 | 1,024 | 1,170 | 1,186 | 738 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 8 | 12 | 20 | 34 | 79 | 223 | 237 | 169 | 157 | 176 |
Revenue
|
|||
| 40.39% | 49.91% | 52.18% | 51.12% | 46.17% | 43.38% | 43.78% | 44.67% | 44.43% | 47.14% |
Gross Margin
|
|||
| (13) | (8) | (10) | (18) | (33) | (274) | (35) | (84) | (104) | (32) |
EBT
|
|||
| (170.70%) | (66.03%) | (48.59%) | (53.83%) | (41.60%) | (123.02%) | (14.79%) | (49.93%) | (66.56%) | (18.26%) |
EBT Margin
|
|||
| (13) | (8) | (10) | (18) | (33) | (276) | (37) | (100) | (115) | 78 |
Net Income
|
|||
| 0 | 1 | 1 | 3 | 10 | 21 | 25 | 30 | 33 | 29 |
Depreciation
|
|||
| 0.54 | 0.52 | 0.70 | 1.02 | 2.04 | 4.85 | 4.84 | 3.46 | 3.18 | 3.52 |
Revenue/Sh
|
|||
| (0.93) | (0.34) | (0.34) | (0.55) | (1.94) | (6.18) | (0.93) | (2.21) | (2.49) | 1.40 |
Earnings/Sh
|
|||
| (0.40) | (0.16) | (0.12) | (0.04) | (0.39) | 0.18 | (0.04) | (0.02) | (0.33) | (0.17) |
Cash Flow/Sh
|
|||
| (0.08) | (0.08) | (0.10) | (0.16) | (0.25) | (0.54) | (0.49) | (0.92) | (0.43) | (0.39) |
Capex/Sh
|
|||
| (0.48) | (0.23) | (0.22) | (0.20) | (0.64) | (0.37) | (0.53) | (0.94) | (0.76) | (0.56) |
Free CF/Sh
|
|||
| 0.40 | 0.78 | 1.37 | 3.78 | 9.92 | 13.97 | 11.35 | 10.03 | 8.14 | 10.04 |
Book Value/Sh
|
|||
| 14 | 23 | 28 | 33 | 39 | 46 | 49 | 49 | 49 | 50 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.27 |
PE Ratio
|
|||
| 5.87 | 16.29 | 15.85 | 16.19 | 21.51 | 12.21 | 3.60 | 4.47 | 2.45 | 2.73 |
PS Ratio
|
|||
| 7.94 | 10.89 | 8.07 | 4.35 | 4.46 | 4.30 | 1.59 | 1.63 | 1.04 | 1.04 |
PB Ratio
|
|||
| 5.45 | 15.14 | 14.24 | 13.44 | 21.83 | 11.22 | 3.11 | 4.02 | 2.13 | 1.46 |
EV/Sales
|
|||
| (6.08) | (33.62) | (44.26) | (67.74) | (70.02) | (147.98) | (28.31) | (14.84) | (8.88) | (9.14) |
EV/FCF
|
|||
| (6) | (4) | (3) | (1) | (15) | 8 | (2) | (1) | (16) | (9) |
Op' Cash Flow
|
|||
| (1) | (2) | (3) | (5) | (10) | (25) | (24) | (45) | (21) | (20) |
Capex
|
|||
| (7) | (5) | (6) | (7) | (25) | (17) | (26) | (46) | (38) | (28) |
FCF
|
|||
| 4 | 15 | 49 | 98 | 112 | 651 | 563 | 490 | 277 | 257 |
Working Cap'
|
|||
| 1 | — | 15 | 1 | 118 | 409 | 407 | 381 | 200 | 2 |
Total Debt
|
|||
| (4) | (15) | (33) | (93) | 25 | (219) | (116) | (76) | (50) | (409) |
Net Debt
|
|||
| 6 | 18 | 39 | 126 | 383 | 642 | 556 | 489 | 402 | 503 |
Sh' Equity
|
|||
| (189.28%) | (55.67%) | (24.86%) | (19.05%) | (21.80%) | (34.07%) | (4.21%) | (10.78%) | (14.78%) | 9.57% |
ROA
|
|||
| (304.99%) | (173.41%) | (89.55%) | (33.48%) | (4.60%) | (2.64%) | (4.53%) | (15.20%) | (21.63%) | (24.67%) |
ROIC
|
|||
| (300.55%) | (67.03%) | (33.87%) | (22.24%) | (29.65%) | (56.10%) | (7.76%) | (21.51%) | (29.57%) | 16.98% |
ROE
|
|||
CryoPort, Inc. peers in Integrated Freight & Logistics
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FWRD Forward Air Corporation | $498.3M | 0.0× | Compare |
| HUBG Hub Group, Inc. | $1.8B | 17.3× | Compare |
| RLGT Radiant Logistics, Inc. | $400.0M | 21.3× | Compare |
| PBI Pitney Bowes Inc. | $2.2B | 13.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GXO GXO Logistics, Inc. | $5.1B | 39.3× | Compare |
| LSTR Landstar System, Inc. | $5.6B | 42.4× | Compare |
| PAL Proficient Auto Logistics, Inc. | $106.0M | 0.0× | Compare |
| PSIG PS International Group Ltd. | $73.7M | 0.0× | Compare |
CryoPort, Inc. (CYRX) key facts
- CryoPort, Inc. (CYRX) is an Integrated Freight & Logistics company in the Industrials sector, listed on Nasdaq.
- As of September 25, 2026, CYRX traded at $17.41, a market capitalization of $881.3 million.
- Return on equity was 17.0% and debt-to-equity 0.38.
CryoPort, Inc. (CYRX) Latest News
14 Aug
Cryoport (CYRX) Q2 2026 earnings call transcript released covering financial results, operations and outlook. Earnings call transcript reveals financial performance and strategic outlook that can significantly shift investor views and stock trajectory.
7 Aug
CryoPort pipeline expansion strengthens investor confidence in the company. Pipeline expansion signals major strategic progress likely to shift company trajectory and sentiment.
CryoPort Inc achieved positive EBITDA milestone in Q2 2026 earnings call along with 15% growth in key metrics, marking improved operational performance. Positive EBITDA milestone directly strengthens financial outlook and investor confidence in core operations.
CryoPort, Inc. conducted its Q2 2026 earnings call covering financial results, operational updates and forward outlook for cryogenic logistics services. Quarterly earnings releases typically produce moderate share-price movement and valuation adjustments.
6 Aug
CryoPort Inc. held its Q2 earnings call and provided highlights on financial results and operations. Q2 earnings call delivers updates on results and outlook with moderate effect on near-term stock sentiment.
CryoPort, Inc. posted a Q2 loss but exceeded revenue estimates. Q2 earnings with a revenue beat can shift near-term financial perception and stock reaction.
CryoPort reported its second quarter 2026 financial results. Quarterly results deliver performance metrics that shape near-term valuation and sentiment.
27 Jul
Analysts lifted price targets for CryoPort (CYRX) citing growth trends, resulting in higher stock fair value. Lifted analyst targets on growth trends moderately affect CryoPort future performance and market perception.
13 Jun
Analysts revised CryoPort bioservices outlook upward, lifting CYRX stock fair value. Bioservices outlook revision raises CYRX fair value and may shift near-term investor views.
4 May
CryoPort, Inc. Q1 2026 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings details financial performance and strategic outlook poised to significantly sway investor sentiment and stock trajectory.
CryoPort (CYRX) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Quarterly earnings transcripts disclose revenue, profitability, and strategic plans that drive investor sentiment and stock price movements.
Cryoport (CYRX) Q2 2025 earnings call transcript details quarterly financial results, operational updates, and management outlook. Q2 2025 earnings transcript reveals financial performance, guidance, and strategic insights directly influencing CYRX investor sentiment and stock trajectory.
CryoPort (CYRX) Q1 2025 earnings call transcript covers quarterly financial results, operational highlights, strategic updates, and forward-looking guidance. Q1 2025 earnings transcript reveals financial performance and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.
CryoPort (CYRX) released Q3 2025 earnings call transcript detailing quarterly financial results, operational updates, and management outlook. Q3 2025 earnings transcript discloses financial performance and strategic guidance significantly influencing CYRX's market trajectory and investor sentiment.
CryoPort, Inc. (CYRX) reported first quarter 2026 financial results. Quarterly financial results disclosure significantly impacts stock performance and investor sentiment.
CryoPort, Inc. (CYRX) Q1 earnings call highlights key financial results, operational updates, and forward guidance for the quarter. Q1 earnings call highlights detail financial performance and strategic outlook, exerting moderate influence on investor sentiment and stock trajectory.
CryoPort, Inc. (CYRX) reported a Q1 net loss but exceeded revenue estimates. Q1 revenue beat offsets net loss, creating moderate influence on financial performance and investor sentiment.
4 Mar
CryoPort, Inc. (CYRX) Q4 2025 earnings call summary highlights quarterly financial results, operational updates, strategic progress, and forward-looking guidance for the cryopreservation logistics leader. Q4 earnings summaries deliver key financial metrics, growth strategies, and outlook that significantly shape investor expectations and stock trajectory.
CryoPort Inc (CYRX) Q4 2025 earnings call highlights record growth in cell and gene therapy revenue. Record growth in cell and gene therapy revenue demonstrates strong performance in CryoPort's core operations, likely enhancing future market position and investor sentiment.
3 Mar
CryoPort, Inc. (CYRX) released highlights from its Q4 earnings call, detailing financial results and strategic updates. Q4 earnings call highlights reveal financial performance and guidance that can significantly sway investor sentiment and stock trajectory.
CryoPort (CYRX) Q4 2025 earnings call transcript released, covering financial results, operations, and outlook. Q4 earnings call transcript reveals financial performance and guidance, significantly influencing stock trajectory and investor sentiment.
CryoPort, Inc. (CYRX) reported fourth quarter and full-year 2025 financial results. Quarterly and annual earnings reports significantly impact financial performance assessments and investor sentiment.
CryoPort, Inc. (CYRX) reported a Q4 net loss but exceeded revenue estimates. Q4 net loss offset by revenue beat suggests moderate impact on financial performance and investor sentiment.
11 Feb
Cryoport, Inc.'s MVE Biological Solutions has launched the new Fusion® 800 Series, designed to enhance temperature-controlled shipping solutions for the life sciences sector. This innovative series aims to improve the efficiency and reliability of transporting biological materials, addressing the growing demand for advanced logistics in the biopharmaceutical industry. The Fusion® 800 Series features enhanced insulation and temperature stability, catering to the needs of various applications, including cell and gene therapies. The introduction of the Fusion® 800 Series is a significant strategic move that could enhance CryoPort's competitive positioning in the growing biopharmaceutical logistics market.
7 Dec
Recent developments at CryoPort, Inc. (CYRX) indicate a positive shift in the company's valuation outlook, driven by strategic partnerships and advancements in its logistics solutions for the biopharmaceutical sector. These changes are expected to enhance operational efficiency and expand market reach, positioning CryoPort favorably in a competitive landscape. Investors are optimistic about the potential for increased revenue and market share as the company leverages its innovative technologies and services. Strategic partnerships and advancements in logistics solutions are likely to significantly enhance operational efficiency and market positioning.
22 Nov
CryoPort, Inc. has made strategic gains that are expected to shift analysts' perspectives on the company's future. Recent market changes and advancements in their operations position CryoPort favorably within the biopharmaceutical logistics sector. Analysts are optimistic about the company's ability to leverage these developments to enhance its competitive edge and financial performance, indicating a potential positive trajectory ahead. Recent strategic gains and market changes are likely to significantly impact CryoPort's future performance and investor sentiment.
7 Nov
Recent developments surrounding CryoPort, Inc. (CYRX) have drawn attention from analysts and the market, highlighting shifts in investor sentiment and potential impacts on the company's future. Analysts have provided updated ratings and insights, reflecting changes in market dynamics and competitive positioning. These factors may influence CryoPort's operational strategies and financial performance moving forward. Analyst updates and market reactions are expected to moderately influence CryoPort's competitive positioning and financial performance.
6 Nov
CryoPort, Inc. has been awarded the 2025 BioTech Breakthrough Award for 'BioServices Innovation of the Year' due to its advancements in biostorage and logistics solutions for the life sciences industry. This recognition highlights the company's commitment to innovation and excellence in providing critical services for the transportation and storage of biological materials. Winning a prestigious award enhances CryoPort's reputation and could significantly influence its market position and investor sentiment.
CryoPort, Inc. (CYRX) is facing challenges with profitability as it approaches earnings reports, despite a focus on discounted sales valuation. Investors are concerned about the company's ability to generate consistent profits, which remains elusive. The market is closely watching how these factors will influence future performance and investor sentiment. Profitability concerns and discounted sales valuation may moderately influence investor sentiment and financial performance.
5 Nov
CryoPort, Inc. (CYRX) reported double-digit growth in its Q3 2025 earnings call, highlighting strategic initiatives aimed at enhancing operational efficiency and expanding market reach. The company emphasized its commitment to innovation and customer service, which are expected to drive future revenue growth. Management provided insights into ongoing projects and partnerships that align with their long-term vision, reinforcing confidence in the company's trajectory. Significant strategic initiatives and growth in earnings suggest a strong potential for future performance and market positioning.